The Venn Difference
Rooted in Science
Advanced biotech R&D, genomics, tissue culture, and secondary metabolite production.
Scaled for Commerce
Multi-vertical platform strategy, B2B partnerships, and revenue-generating models.
Aligned with Policy
Biodiversity conservation, EU funding integration, and sustainable impact.
Featured Platforms
GEOCON
LaunchGeophytes (bulbous plants) · Cosmetics, Pharma, Ornamentals
From endangered bulbous plants to cosmetic and pharmaceutical markets — powered by tissue culture and advanced biotech.
Investment Highlights
$113.7B
Market Size
Cosmetics + Pharma + Ornamentals (2024)
6–20%
CAGR
Across target market segments
3+
Countries
Turkey, Estonia, Chile (expanding)
7+
Platforms
GEOCON + 6 in pipeline
$1B+
Unicorn Potential
Aggregate portfolio value
Platform Architecture
5 modules. One operating system.
Every VENN platform — from GEOCON to future verticals — runs on the same modular architecture. Atlas selects. Lab validates. Farm Network scales. Market sells. Academy & Policy legitimises.
Why Invest in Venn
Capital-Efficient Growth
Combines EU grants (non-dilutive) with private capital (dilutive) for optimised funding structure. Lower burn, higher leverage.
Multi-Vertical Diversification
7+ platform pipeline reduces market risk through portfolio approach. Each platform independently viable; together, compounding.
IP-Protected Ecosystem
Hybrid IP protection — patents, trademarks, trade secrets, licenses — creates deep defensibility and recurring revenue.
Unicorn Potential
Aggregate portfolio value across platforms and spin-offs targets $1B+ valuation. GEOCON alone addresses $113.7B addressable market.
Ready to Transform Science Into Venture?
Connect with our team to explore investment opportunities, partnerships, or collaboration.